trending Market Intelligence /marketintelligence/en/news-insights/trending/isvokzonydug6qvolcar7g2 content esgSubNav
In This List

Abattis Bioceuticals starting share buyback program

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises

Blog

Essential IR Insights Newsletter - Summer July-August 2023

Blog

Insight Weekly: Climate law faces hurdles; US borrowing surges; banks revise uninsured deposits


Abattis Bioceuticals starting share buyback program

Abattis Bioceuticals Corp. plans to repurchase 20,986,909 common shares, representing 5% of its current issued and outstanding stock.

President and CEO Rob Abenante said that management "believes that, compared to its market peers, the company's shares are undervalued."

The normal course issuer bid for the purchase of the common shares will begin Aug. 15, 2018, and terminate Aug. 15, 2019. Any common shares purchased under the bid will be canceled by the company.

The Vancouver, British Columbia-based cannabis company said all common shares will be bought on the open market via the facilities of the Canadian Securities Exchange.